Communiqués AbbVie Inc.

Actions

ABBV

US00287Y1091

Produits pharmaceutiques

Temps réel estimé Cboe BZX 18:12:26 18/09/2026			Varia. 5j.	Varia. 1 janv.
263,81 ^USD	-0,08%		+2,80%	+15,68%

15:38	Des données positives pour AbbVie
15:36	AbbVie présente de nouvelles données en vie réelle soutenant l'efficacité du VRAYLAR (cariprazine) au Psych Congress 2026	CI

Communiqués

14:32	AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026	PR
11:23	AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society Meeting	AQ
11:22	AbbVie - Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	AQ
17/09	AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting	PR
17/09	Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	PR
15/09	AbbVie and BioLabs University of Toronto Open Applications for AbbVie Biotech Innovators Award at Life Sciences Ontario Forum	AQ
15/09	AbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaign	PR
15/09	Allergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin Summit	PR
10/09	AbbVie Declares Quarterly Dividend	PR
10/09	AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine	PR
03/09	AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma	PR
03/09	AbbVie Completes Acquisition of Apogee Therapeutics	PR
03/09	AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference	PR
02/09	Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care	PR
01/09	A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture	PR
01/09	SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings	PR
31/08	AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference	PR
27/08	AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease	PR
21/08	AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline	PR
18/08	AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support	PR
11/08	Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices	PR
05/08	UBRELVY(R) (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency (CDA-AMC) for Acute Migraine Treatment	AQ
04/08	Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence	PR
04/08	UBRELVY® (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency (CDA-AMC) for Acute Migraine Treatment	AQ
31/07	AbbVie: Q2 Earnings Snapshot	AQ